Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Patients 18 years of age or older and on a stable dose of lipid therapy

Exclusion Criteria:

• Patients lipid level is outside the recommended range

• Patients that are HIV positive